Coherus Oncology (CHRS) Common Equity (2012 - 2026)

Coherus Oncology has disclosed Common Equity across 15 years of filings, most recently posting $78.6 million for Q1 2026.

• Common Equity for Q1 2026 came in at $78.6 million, up 142.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $78.6 million (up 142.85% YoY), and the FY2025 annual result was $61.0 million, up 146.23% from the prior year.
• Common Equity came in at $78.6 million for Q1 2026 at Coherus Oncology, up from $61.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $119.8 million in Q2 2025 to a low of -$196.5 million in Q1 2023.
• The 5-year median for Common Equity is -$88.0 million (2024), against an average of -$68.5 million.
• Across the five-year window, Common Equity slumped 1664.17% in 2023 and surged 242.47% in 2025, its largest moves.
• Coherus Oncology's Common Equity stood at -$137.4 million in 2022, then slumped by 40.76% to -$193.4 million in 2023, then soared by 31.76% to -$132.0 million in 2024, then surged by 146.23% to $61.0 million in 2025, then gained by 28.86% to $78.6 million in 2026.
• The last three Common Equity figures came in at $78.6 million (Q1 2026), $61.0 million (Q4 2025), and $87.8 million (Q3 2025), per Business Quant data.